**GLCCI1** rs37973: a potential genetic predictor of therapeutic response to inhaled corticosteroids in Chinese chronic obstructive pulmonary disease patients

Yuan Lei¹, Yiping Gao², Jinkun Chen², Miao Li¹, Xiaomei Wu¹, Qin Ning³, Jianping Zhao¹, Weining Xiong¹, Yongjian Xu¹ & Jungang Xie¹

Inhaled corticosteroids (ICSs) are widely prescribed in chronic obstructive pulmonary disease (COPD). However, little is known about predictors of ICSs therapeutic response. To investigate whether the variation in glucocorticoid-induced transcript 1 (**GLCCI1**) rs37973 is associated with ICS efficacy. A total of 204 clinically stable COPD patients were recruited and administered to inhaled fluticasone propionate/salmeterol combination (500/50 ug, twice daily) for 24 weeks. We genotyped the functional rs37973 and mainly assessed its effects on changes in lung function. In *vitro*, neutrophils isolated from parts of patients were incubated with various concentrations of dexamethasone (0, 10⁻⁶ M and 10⁻⁴ M) in the presence or absence of cigarette smoke extract, apoptosis was then assessed by flow cytometry. Patients with the homozygous GG genotype (increases of 15.3 ± 33.2 mL) had significantly poorer improvement in FEV₁ than those with the AA (92.7 ± 29.6 mL; *p* < 0.001) or AG (59.4 ± 26.9 mL; *p* < 0.001) genotypes after 24-week treatment. In *vitro*, dexamethasone had less inhibitory effect of neutrophil apoptosis on GG genotype, which further validated the presence of mutant allele ‘G’ might negatively affect glucocorticoid responsiveness irrespective of smoking status. The GG genotype of rs37973 may associated with decreased ICSs efficacy in Chinese COPD patients.

Chronic obstructive pulmonary disease (COPD) is a leading and increasing cause of mortality worldwide¹, which lead to persistent airflow limitation, airway remodeling and progressive deterioration in lung function. Cigarette smoking is one of the major risk factors for the ongoing inflammation in airways², and inhaled corticosteroids (ICSs) are the mainstay of anti-inflammatory therapy. Current guidelines recommend the use of ICSs combining with long-acting β₂-agonists for COPD patients at high risk of exacerbations³. However, the efficacy shows high inter-individual variability with numerous patients having insufficient response. And prolonged ICSs therapy carries the risk of local and systemic side effects such as oropharyngeal candidiasis, hoarseness, pneumonia⁴,⁵, osteoporosis etc.⁶ Therefore, identification of patients who are prone to nonresponse is becoming increasingly important.

Recently a novel pharmacogenetic variation in the glucocorticoid-induced transcript 1 gene (**GLCCI1**) has been studied intensively in asthma⁷-¹¹, since Tantisira and colleagues revealed in 2011 that the functional rs37973 polymorphism, which was in complete linkage disequilibrium with rs37972, might substantially cause a decreased response to ICSs therapy in non-Hispanic white asthmatics¹². Subsequently, Van den Berge *et al.* further investigated the effect of **GLCCI1** variant rs37972 on glucocorticoid responsiveness in 63 COPD patients. And then extended the findings of Tantisira *et al.* from asthma to COPD, by showing that **GLCCI1** was also
associated with changes in pulmonary function after ICS therapy in COPD [13]. However, due to small numbers of participants and lack of functional validation, the precise role of **GLCCI1** in COPD was far from definable.

Neutrophilic inflammation is a prominent feature of COPD in airways as well as circulation. This persistent and abnormal inflammation is highly correlate with disease progression, and apoptosis is a crucial resolution for non-phlogistic clearance of neutrophils [14]. However, glucocorticoids delay neutrophil apoptosis in vitro cell culture. That may partly account for relative less effectiveness of ICSs in COPD than asthma [15]. Located in **GLCCI1** promoter region, the mutant allele ‘G’ of rs37973 was confirmed to down-regulate the expression of **GLCCI1** in vitro functional analysis [12]. **GLCCI1** induction was an early maker of apoptosis in glucocorticoid-treated thymoma cells [16]. Hence, we postulated that neutrophils, isolated from COPD patients with different genotypes of rs37973, might also responded differently to glucocorticoids stimulation in vitro.

Unlike asthma, although widely prescribed, very few pharmacogenetics studies in COPD have focused on the role of genetic variants in ICS therapeutic response [17,18]. Based on their findings, we aimed to further investigate whether the functional rs37973 variant is associated with long-term ICS therapeutic response in Chinese COPD patients. Moreover, we aimed to verify the potential predictive value of rs37973 variant in vitro cell study of dexamethasone-mediated neutrophil apoptosis.

**Results**

**Participants.** A total of 209 clinically stable COPD patients were recruited, among them, 204 eligible patients were finally included in our study (4 lost to follow-up and 1 migrated). The demographic characteristics and lung function at baseline were homogeneous between groups stratified by the rs37973 genotype (Table 1). The mean age was 67.0 years old. A total of 79.4% patients were men and 53.4% were current smokers with a history of smoking more than 20 pack-years. The mean post-bronchodilator forced expiratory volume in one second (FEV1) was 1.22 liters, which was 46.31% of the predicted value. All of our patients were in category C or D according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria [3], which meant high risk of COPD exacerbation.

**Genotype and allele frequencies.** About the rs37973 genotype, 59 (28.9%) individuals were homozygous for the major ‘A’ allele, 50 (24.5%) individuals were homozygous for the mutant ‘G’ allele and 95 (46.6%) were AG heterozygotes. The minor allele ‘G’ frequency was 0.478 and all genotype frequencies were in Hardy-Weinberg equilibrium (p = 0.340).

**Association between rs37973 genotype and lung function changes.** After 24-week treatment of ICS, patients with the homozygous GG genotype (increases of 15.3 ± 33.2 mL) had significantly poorer improvement in FEV1 than those with the AA (92.7 ± 29.6 mL; p < 0.001) or AG (59.4 ± 26.9 mL; p < 0.001) genotypes (Fig. 1a). As for FEV1 % of predicted, the GG homozygotes also increased remarkably lower (0.68 ± 1.36%), compared with the AA homozygotes (3.67 ± 1.38%; p < 0.001) or AG heterozygotes (2.40 ± 1.35%; p < 0.001), while the overall mean improvement was 2.33 ± 1.73% (Fig. 1b). In addition, the effect of per mutant allele ‘G’ of rs37973 was estimated by regression analysis (Fig. 2), suggesting that each additional copy of ‘G’ allele corresponded to a lower ICS efficacy (R2 = 0.476, F = 179.23, P < 0.001).

**Effects of smoking status on ICS efficacy.** Consistent with previous studies [19,20], we found that smoking status was significant predictor of changes in FEV1 (Fig. 3). Smokers had significant poor improvement compared with non-smoking patients (46.8 ± 39.0 mL versus 71.0 ± 38.3 mL; p < 0.001), after adjusting for age, sex and baseline percentage of predicted FEV1. As for changes in FEV1 % of predicted, similar results were observed in smoking and non-smoking patients (unadjusted for covariates, 1.86 ± 1.61% versus 2.89 ± 1.72%; p < 0.001).
Effects of rs37973 genotype on dexamethasone-mediated neutrophil apoptosis. A total of 43 voluntary patients provided an extra 8 ml venous blood for neutrophil culture in vitro, among them, the numbers of AA, AG and GG genotypes of rs37973 were 11, 14 and 18, respectively. Dexamethasone significantly inhibited spontaneous neutrophil apoptosis irrespective of genotype in a concentration-dependent (0, 10^{-6} M and 10^{-4} M) manner under standard culture conditions for 18 h (Fig. 4a). Interestingly, we found that neutrophils isolated from patients with GG genotype didn't show corresponding reductions in apoptosis at 10^{-6} M, compared with solvent control (the percentage of apoptotic cells: 72.03 ± 2.06% versus 72.27 ± 1.33%; p = 0.903).

Previous studies have reported that dexamethasone caused a concentration-dependent inhibition of neutrophil apoptosis, usually evident at 10^{-8} M and maximal at 10^{-6} M of clinically relevant drug concentrations\textsuperscript{21-23}. Similar anti-apoptotic effects were also confirmed in AA and AG genotypes of rs37973 in our study. However, since dexamethasone at 10^{-6} M had little effect on GG genotype, we extended our experimental concentration to 10^{-4} M, higher than clinically relevant drug concentrations. Only then did we observed an expected suppression of neutrophil apoptosis by dexamethasone in GG genotype (67.03 ± 1.74% versus 72.27 ± 1.33%; p = 0.004). In addition, we observed that neutrophils isolated from patients with AA genotype had significantly decreased percentage of apoptosis compared with those of GG genotype in the presence of both 10^{-6} M (59.68 ± 5.80% versus 72.03 ± 2.06%; p = 0.025) and 10^{-4} M (53.64 ± 5.88% versus 67.03 ± 1.74%; p = 0.013) dexamethasone, suggesting that dexamethasone had less inhibitory effect on GG genotype (Fig. 4b).

Dexamethasone attenuated CSE-induced neutrophil apoptosis. Cigarette smoke extract (CSE), used in isolated neutrophils system as the underlying inflammatory milieu, could significantly promote neutrophil apoptosis comparing with sham-treated cells of all genotypes. For AA and AG genotypes, dexamethasone reduced the pro-apoptotic effect of CSE in a concentration-dependent manner (10^{-6} M and 10^{-4} M), compared with merely CSE-treated cells (Fig. 5a,b,d). However, we didn't observe the same effect of dexamethasone on GG genotype at a concentration of 10^{-6} M (Fig. 5c), which was similar to culturing without CSE milieu. CSE-induced neutrophil apoptosis could only be slightly attenuated by a relatively higher concentration (10^{-4} M) of dexamethasone (73.63 ± 3.58% versus 81.94 ± 2.45%; p = 0.032).
Discussion

In our study, we confirmed that GLCCI1 rs37973 was an important determinant of decreased ICSs therapeutic response in COPD. Patients with homozygous mutant 'G' genotype had significantly poor improvement in lung function after 24 weeks of ICS treatment. Moreover, we validated the potential predictive value of rs37973 variant on corticosteroid responsiveness in vitro experiments, showing that dexamethasone had less anti-apoptotic effects on neutrophils isolated from patients with the GG genotype.

Following up the findings of Tantisira et al. in asthma11, Van den Berge and colleagues firstly investigated the role of GLCCI1 rs37972 polymorphism in ICS therapeutic response in 63 Dutch COPD patients. After 3 and 30 months treatment of fluticasone with or without added salmeterol, the major allele homoyzgotes had remarkably greater improvement in FEV1 than those with the homozygous mutant genotypes, indicating that GLCCI1 was also associated with ICS responsiveness in COPD13. On the basis of Van den Berge et al., a larger sample set, 402 non-Hispanic white COPD patients drawn from two GSK-sponsored clinical studies, were treated with fluticasone furoate monotherapy for 12 weeks. However the results were contrary, showing that the GLCCI1 rs37973 polymorphism, which was highly correlated with rs37972, didn’t have an effect on FEV1 response24. Considering the small sample size of Van den Berge et al.’s research, the initial association might be a false positive. However, on the other side, ICS monotherapy is not recommended by guidelines1, for it is less effective than combination with long-acting β2-agonists. The subjects in GSK study had a lower baseline FEV1 % of predicted and received exclusively ICS monotherapy for only 12 weeks, which might lead to a relative false negative. In addition, the controversial conclusion might also partly result from different ethnicities. To better elucidate the possible role of GLCCI1 in COPD, our research then selected a well-characterized population of 204 Chinese clinical stable COPD patients, and all the patients received inhaled fluticasone propionate added salmeterol therapy for 24 weeks. Combining with in-vitro cell functional validated, our findings further confirmed that the functional rs37973 polymorphism held the potential to be a novel genetic predictor of ICS therapeutic response in Chinese COPD patients.

Consistent with previous researches in asthma, the functional rs37973 variant in GLCCI1 was first identified to cause substantial decrements in ICS therapeutic response in 935 white non-Hispanic adults and children by Tantisira et al.12, and subsequently validated in 402 European asthmatic children9 and 224 Japanese adult patients8. However, the role of rs37973 has recently been challenged by a larger well-designed replication study in 7 GSK-sponsored clinical trials including 1924 non-Hispanic white asthmatics, by showing that rs37973 didn’t significantly influence changes in FEV1 after 8 or 12 weeks of ICSs treatment6. Possible explanations for this discrepant evidence might be divergent end points, different treatment durations and ethnic variations. Both COPD and asthma are chronic airway inflammation characterized by airflow limitation and probably share a common genetic background according to Dutch hypothesis25. Notwithstanding the similarities, patients with COPD are generally less responsive to corticosteroids than asthmatics, which may partly result from the distinct difference in key inflammatory cells involved in COPD (neutrophils, macrophages, CD8+ lymphocytes)28 and asthma (eosinophils, CD4+ lymphocytes)26. As previous studies have shown that glucocorticoids inhibit neutrophil apoptosis while promote eosinophil apoptosis at clinically relevant drug concentrations, usually between 10−10 M and 10−6 M in vitro cell culture23,28,29. Though pharmacogenetics may display a class effect in various disease, considering the differences between COPD and asthma, the effect of rs37973 variant on corticosteroid responsiveness should be interpreted with caution and further prospective validations will be required in both COPD and asthma.

To the best of our knowledge, only one other genetic variant, rs242941 in the corticotrophin releasing hormone receptor 1 (CRHR1) had been reported as a probable determinant of corticosteroid responsiveness in COPD18. However, the study of Kim et al. was small with only 12-week follow-up observation in a total of 87 patients and due to lack of further validation, the role of CRHR1 in COPD was still indefinable. Although ICSs are
widely or even over prescribed\textsuperscript{30}, only very few studies demonstrated markers that might associated with corticosteroid responsiveness in COPD. And most of them are limited to short-term response or uncertain clinical features such as bronchodilator responsiveness\textsuperscript{31}, frequent exacerbation\textsuperscript{32}, sputum eosinophilia etc\textsuperscript{33}. No predictors of long-term responsiveness has been established. Thus our research herein highlights a promising new approach of pharmacogenetics to predict long-term ICSs therapeutic efficacy in COPD.

Cigarette smoking is not only the most important cause of COPD, but also associated with accelerated pulmonary function decline and decreased corticosteroid responsiveness\textsuperscript{2,34}. Our research confirmed those of previous
studies by showing that smokers had significant poor improvement in FEV1 after 24-week ICS therapy. Therefore, smoking cessation is an essential therapeutic strategy for COPD.

In vitro functional validation, consistent with previous studies21–23, we observed that dexamethasone inhibited spontaneous neutrophil apoptosis in a concentration-dependent manner under standard culture conditions. Interestingly, in the presence of 10−6 M dexamethasone, which was thought to be the maximal inhibitory concentration24, neutrophils isolated from patients with the GG genotype of rs37973 didn’t show corresponding reductions in apoptosis with or without CSE milieu. Only when we extended our experimental concentration to 10−4 M, did we observed an expected inhibitory effort. In keeping with our clinical related findings, those results further validated the negative effect of mutant allele ‘G’ on corticosteroid responsiveness irrespective of smoking status.

Since apoptosis helps eliminate granulocytes without releasing histotoxic mediators and limit tissue injury, to some extent, an inappropriate delay in apoptosis may be detrimental to control neutrophilic inflammation. Thus, inhibition of neutrophil apoptosis didn’t result in concomitant better clinical response, our experiments could only verify neutrophils with GG genotype responded less to glucocorticoids in vitro, neutrophil apoptosis couldn’t act as an indicator of changes in lung function after ICS therapy. However, Marwick et al. reported that under severe hypoxic conditions, glucocorticoids lost their ability to promote neutrophil survival and could even reduce the pro-survival effect of inflammatory mediators like GM-CSF, suggesting that glucocorticoids might not account for augmenting neutrophil survival at sites of inflamed tissues21. As potent but nonspecific anti-inflammatory drugs, glucocorticoids in COPD are more likely to exert their anti-inflammatory effects through inhibiting lymphocytic inflammation35, increasing epithelial barrier function, decreasing oxidative stress etc.36. The immunopathogenesis of COPD is quite intricate with various inflammatory cells, cytokines and their interactions in different surrounding environment37, thus further research imitating in-vivo inflammatory environments is clearly needed to investigate the exact anti-inflammatory mechanisms of glucocorticoids in COPD.

However, there are certain limitations in our study. We recruited a selective group of homogeneous COPD patients in a Han Chinese population. Since genetic distribution varies between ethnicities, our results may not generalize to other ethnic groups. Additionally, we only investigated one single potential genetic predictor, which was far from accurately predict ICs efficacy in COPD. As McGeachie et al. reported that even combination of just two genetic variants, GLCCI1 and CRHR1, could achieve better accuracy in predicting ICs therapeutic response of asthmatics38. Although little is known about predictors of corticosteroid responsiveness in COPD, our study herein shed new light on individualized treatment for COPD, indicating that pharmacogenetic may become a promising new approach to predict long-term ICs efficacy.

Another limitation is that combination therapy with ICS and long-acting β2-agonists (fluticasone propionate/salmeterol) was used in our study, ICs therapeutic response might be influenced by the β2-agonists in some degree. The exact effect of long-acting β2-agonists on ICS is uncertain, but they are believed to have a synergistic interaction34. Indeed, COPD patients benefit better from combination therapy than ICS monotherapy, and it’s widely used in practice as recommended by guidelines3. But then, we further verified the effect of rs37973 variant on corticosteroid responsiveness in vitro cell study. Despite these limitations, we are confident that our principal findings are reliable since the clinical trial and cell experiments consistently indicated the presence of mutant allele ‘G’ might negatively affect corticosteroid responsiveness irrespective of smoking status.

In conclusion, our study reveals that the GG genotype of rs37973 is associated with decreased ICs efficacy in clinically stable COPD patients in a Han Chinese population.

| Characteristic                  | Total (N = 204) | AA (N = 99) | AG (N = 95) | GG (N = 50) | p value |
|--------------------------------|----------------|-------------|-------------|-------------|--------|
| Male sex                       | 162 (79.4)     | 42 (71.2)   | 79 (83.2)   | 41 (82.0)   | 0.177  |
| Age (years)                    | 67.0 ± 12.6    | 68.1 ± 11.8 | 66.7 ± 12.8 | 66.4 ± 13.2 | 0.739  |
| Current smoker                 | 109 (53.4)     | 30 (50.8)   | 49 (51.6)   | 30 (60.0)   | 0.561  |
| Pack-years smoked              | 26.6 ± 31.2    | 29.5 ± 37.2 | 24.7 ± 30.8 | 26.7 ± 23.8 | 0.645  |
| GOLD stage at enrollment       |                |             |             |             | 0.125  |
| 30–50%: GOLD 3                 | 71 (34.8)      | 17 (28.8)   | 41 (43.2)   | 13 (26.0)   |        |
| <30%: GOLD 4                   | 48 (23.5)      | 12 (20.3)   | 21 (22.1)   | 15 (30.0)   |        |
| Other category                 | 85 (41.7)      | 30 (50.8)   | 33 (34.7)   | 22 (44.0)   |        |
| FEV1 at baseline (L)           | 1.22 ± 0.59    | 1.29 ± 0.65 | 1.18 ± 0.56 | 1.20 ± 0.60 | 0.511  |
| (% of predicted)               | 46.31 ± 20.06  | 50.69 ± 21.91 | 44.51 ± 18.57 | 44.56 ± 20.10 | 0.138  |

Table 1. Demographic and baseline characteristics of patients according to the rs37973 genotype. Data are presented as number (%) or mean ± standard deviation. P > 0.05 for all characteristics according to the One-Way ANOVA with a Bonferroni post hoc test or Pearson Chi-square Tests. GOLD denotes Global Initiative for Chronic Obstructive Lung Disease. FEV1, forced expiratory volume in one second. Current smokers are patients smoking with more than 20 pack-years. Patients in this category have a history of at least one chronic obstructive pulmonary disease exacerbation in the previous year before screening.
Material and Methods

Participants. From April 2012 through December 2013, a total of 209 outpatients with clinically stable COPD were recruited from Tongji Hospital, Wuhan, China. All the patients were in category C or D according to the GOLD criteria, which defined as a post-bronchodilator FEV1/forced vital capacity ratio less than 70%, FEV1 less than 50% of the predicted value and/or at least one documented COPD exacerbation in the preceding year before screening. In addition, eligible patients were at least 40 years old. Main exclusion criteria were asthma or respiratory tract infections, receipt of systemic or inhaled corticosteroids within 4 weeks, and presence of other diseases that might affect the interpretation of neutrophil counts such as hematological diseases, malignancies, systemic lupus erythematosus etc.

Study design. At enrollment, participants were administered to lung function tests according to the standards of the American Thoracic Society/European Respiratory Society. A detailed questionnaire was given to collect information about symptoms, COPD exacerbation history, smoking status and basic demographics. Then, eligible patients received inhaled fluticasone propionate/salmeterol combination (500/50 ug, twice daily) for the next 24 weeks. A trained nurse instructed inhaler technique for each patient and taken 2 ml venous blood from them for genotyping. In this study, we mainly evaluated ICS therapeutic response in patients with different genotypes, which was defined as changes in FEV1 (i.e. \(FEV_{\text{treatment}} - FEV_{\text{baseline}}\)) after 24 weeks treatment. All the clinical data were collected by the same physician, who was blinded to patients’ genotypes. In addition, an extra 8 ml blood was collected for neutrophil culture in vitro from parts of voluntary patients and was not a prerequisite for enrollment in our study.

A separate written informed consent was obtained from all participants. This study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (IRB ID: 20120401), and was conducted according to the principles of the Declaration of Helsinki. Sample collection and all the experimental methods were performed in accordance with the relevant guidelines and regulations.

DNA extraction and genotyping. All participants were genotyped for the rs37973 polymorphism. Genomic DNA was extracted from 2 ml peripheral EDTA-anticoagulated blood according to the manufacturer’s protocol (Blood Genomic DNA Purification Kit; Tiangen Biotech, Beijing, China). Polymerase chain reaction amplification was performed in a total volume of 12.5 μl containing 6.25 μl of Taqman Universal PCR Master Mix (Applied Biosystems Inc., Foster City, CA, USA), 50 ng of extracted DNA and 300 nM of specific probes and primers (Assay ID: rs37973, A5UACTCL; Applied Biosystems). Reaction conditions were as follows: 95 °C for 10 min, 45 cycles at 95 °C for 15 s and 60 °C for 1 min. Genotypes were then determined by the Allelic Discrimination system using the ABI 7900 HT TaqMan sequence detection system (Applied Biosystems). And 10% of samples were randomly genotyped in technical duplicates.

Neutrophil isolation and culture. Neutrophils were isolated from peripheral blood by hydroxyethyl starch sedimentation, Ficoll–Hypaque density gradient centrifugation (TBD, Tianjin, China) and hypotonic lysis of contaminating erythrocytes (Becton Dickinson, Franklin Lakes, NJ, USA). The isolated cells were washed twice and resuspended in RPMI 1640 medium (Life Technologies/GIBCO, Carlsbad, CA, USA) containing 10% fetal bovine serum at 1 × 10^6 cells/ml. Neutrophil viability consistently exceeded 90%, as determined by trypan blue exclusion test. The cell suspension was then transferred equally to 6-well non-adherent culture plates (Corning, NY, USA), and divided into two groups: with or without 10 μg/ml cigarette smoke extract (Murty Pharmaceuticals, Inc., Lexington, KY, USA). Cells of both groups were stimulated with different concentrations of dexamethasone (Sigma) 0, 10^{-6} M and 10^{-4} M in a solvent of dimethyl sulphoxide and were incubated in a humidified incubator (95% air, 5% CO2, 37 °C) for 18 hours. All experiments were performed in triplicate and repeated three times.

Detection of apoptosis by flow cytometry. After incubation, the percentage of neutrophil apoptosis was quantitatively determined by Annexin V-FITC Apoptosis Detection Kit (KeyGen, Nanjing, China) according to the manufacturer’s protocol. In brief, cells were harvested, washed once with ice-cold phosphate-buffered saline and then resuspended in 400 μl Annexin V binding buffer. After incubating with 4 μl Annexin V-FITC (Ann V) for 10 min at room temperature in the dark, 4 μl propidium iodide (PI) were added and incubated for another 5 min. All the experimental procedures were strictly operated on ice. Samples were then immediately run on a Becton Dickinson LSR flow cytometer with data analyzed by CellQuest software. The normal viable cells were defined as Ann V^-/PI^-, early apoptotic cells Ann V^-/PI^+, late apoptotic or necrotic cells were Ann V^-/PI^+ as a result of membrane damage.

Statistical analysis. Categorical variables in baseline characteristics were compared with Pearson chi-square tests and continuous variables with one-way ANOVA, Bonferroni post hoc tests. Hardy-Weinberg equilibrium was analyzed, using chi-square test to compare the observed genotype frequencies with those expected genotype frequencies. The effect of rs37973 variant on changes in lung function after 24 weeks of ICS treatment was assessed by general linear model without adjustment, because of the homogeneous baseline stratified by genotype. Linear regression was used to estimate the effect of per minor allele ‘G’ of rs37973 (coded as 0, 1, or 2) on changes in FEV1.

In addition to rs37973 genotype, stepwise multiple linear regression was performed as an exploratory analysis of factors that could affect ICS therapeutic response, since previous studies have shown that age, sex, baseline percentage of predicted FEV1 and smoking status affect changes in FEV1. Smoking status was significant predictor of changes in FEV1 in our study, and then we repeated our analyses with an additional factorial analysis of
covariance. Fixed effects were smoking status and rs37973 genotype, with three covariates: age, sex and baseline percentage of predicted FEV1. Analyses of dexamethasone-mediated neutrophil apoptosis were performed by two-tailed paired t-tests or independent-samples t-tests, when compared within or between the rs37973 genotype. Statistical analyses were performed using IBM SPSS Statistics 22.0 on Windows (SPSS Inc., Chicago, IL, USA) and p value less than 0.05 was considered statistically significant.

Data Availability. This study was registered in the Chinese Clinical Trials Registry, http://www.chictr.org.cn/; registration number, ChiCTR-ROB-15005824. Date of registration, 2015-01-05.

References

1. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 385, 117–171 (2015).
2. Hooper, R. et al. Risk factors for COPD sputum phenotyping as defined by the lower limit of normal in the BOLD project. Eur. Respir. J. 39, 2554–2563 (2012).
3. Vestbo, J., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 187, 347–365 (2013).
4. Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775–789 (2007).
5. Marzoratti, L., Iannella, H. A. & Waterer, G. W. Inhaled corticosteroids and the increased risk of pneumonia. Ther. Adv. Respir. Dis. 7, 219–224 (2013).
6. Battaglia, S., Cardillo, I., Lavorini, F., Spatafora, M. & Scichilone, N. Safety considerations of inhaled corticosteroids in the elderly. Drugs Aging 31, 787–806 (2014).
7. Izhara, Y. et al. GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids. Allergy 69, 668–673 (2014).
8. Hosking, L. et al. GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. J. Allergy Clin. Immunol. 133, 587–589 (2014).
9. Thompson, B. et al. S31 Variation at GLCCI1: Association with Increased Steroid Dose But Not Adrenal Suppression in Asthmatic Children. Thorax 67, A17.12–A17.12 (2012).
10. McGeehan, M. J. et al. Predicting inhaled corticosteroid response in asthma with two associated SNPs. Pharmacogenomics J. 13, 306–311 (2013).
11. Hu, C. et al. GLCCI1 Variation Is Associated with Asthma Susceptibility and Inhaled Corticosteroid Response in a Chinese Han Population. Arch. Med. Res. 47, 118–125 (2016).
12. Tantisira, K. G. et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365, 1173–1183 (2011).
13. van den Berge, M., Huijts, P. S. & Postma, D. S. Genetics of glucocorticoids in asthma. N. Engl. J. Med. 365, 2434–2435; author reply 2435–2436 (2011).
14. Hoenderdos, K. & Condiffe, A. The neutrophil in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 48, 531–539 (2013).
15. Marwick, J. Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 297 (2010).
16. Chapman, M. S., Askew, D. J., Kauczok, U. & Miesfeld, R. L. Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. Mol. Endocrinol. 10, 967–978 (1996).
17. Hizawa, N. Pharmacogenetics of chronic obstructive pulmonary disease. Pharmacogenomics 14, 1215–1225 (2013).
18. Kim, W. J. et al. Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. Respir. Med. 146, 260–263 (2009).
19. Celli, B. R. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 178, 332–338 (2008).
20. Scanlon, P. D. et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 161, 381–390 (2000).
21. Marwick, J. A. et al. Oxygen levels determine the ability of glucocorticoids to influence neutrophil survival in inflammatory environments. J. Leukoc. Biol. 94, 1285–1292 (2013).
22. Cox, G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J. Immunol. 154, 4719–4725 (1995).
23. Zhang, X., Moilanen, E. & Kankaanranta, H. Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur. J. Pharmacol. 431, 365–371 (2001).
24. GlaxoSmithKline. PGIx6951: Analysis of influence of GLCCI variant rs37973 on inhaled corticosteroid response in COPD patients treated with fluticasone furoate in HZC112206 and HZC112207 https://www.gsk-clinicalstudyregister.com/study/200367 (2014).
25. Postma, D. S., Kerkhof, M., Boezen, H. M. & Koppelman, G. H. Asthma and chronic obstructive pulmonary disease: common genes, common environments? Am. J. Respir. Crit. Care Med. 183, 1588–1594 (2011).
26. Hogg, J. C. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 2645–2653 (2004).
27. Barnes, P. J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 8, 183–192 (2008).
28. Nittou, T. et al. Effects of glucocorticoids on apoptosis of infiltrated eosinophils and neutrophils in rats. Eur. J. Pharmacol. 354, 73–81 (1998).
29. Meagher, L. C., Cousin, J. M., Seckl, J. R. & Haslett, C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156, 4422–4428 (1996).
30. Telenga, E. D., Kerstjens, H. A., Postma, D. S. & ten Hacken, N. H. & van den Berge, M. Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. Expert Opin. Pharmacother. 11, 405–421 (2010).
31. Bleeker, E. R., Emmett, A., Crater, G., Knobli, K. & Kalberg, C. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Palms. Pharmacol. Ther. 21, 682–688 (2008).
32. Miravitlles, M., Soler-Cataluna, J. J., Calle, M. & Soriano, J. B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur. Respir. J. 41, 1252–1256 (2013).
33. Kitaguchi, Y., Komatsu, Y., Fujimoto, K., Hanaka, M. & Kubo, K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 283–289 (2012).
34. Anthonisen, N. R., Connell, J. E. & Murray, R. P. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 166, 675–679 (2002).
35. Jen, R., Rennard, S. I. & Sin, D. D. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Int. J. Chron. Obstruct. Pulmon. Dis.* 7, 587–595 (2012).
36. Lapperre, T. S. et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. *Ann. Intern. Med.* 151, 517–527 (2009).
37. Holloway, R. A. & Donnelly, L. E. Immunopathogenesis of chronic obstructive pulmonary disease. *Curr. Opin. Pulm. Med.* 19, 95–102 (2013).
38. Cazzola, M. & Dahl, R. Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. *Chest* 126, 220–237 (2004).
39. Miller, M. R. *et al.* Standardisation of spirometry. *Eur. Respir. J.* 26, 319–338 (2005).

**Acknowledgements**
This study was supported by the National Natural Science Foundation of China (No. 81570033, 81570047, 81470227, 81370145, 81370156), National Key Basic Research and Development Program (973 Program, No. 2015CB553403), Chinese Medical Association Research Project (No. 2013BAI09B00), National Key Technologies R&D Program (2016YFC1303900 and 2016YFC1304700) and Changjiang Scholars and Innovative Research Team in University (No. IRT_14R20).

**Author Contributions**
J.X. is the guarantor of the manuscript. J.X., Y.X. and W.X., designed and conducted the clinical study. Y.L. and Y.G. had full access to all of the data and takes responsibility for the integrity of the data and the accuracy of the data analysis. J.X., Y.X., Y.L. and Y.G. contributed writing the manuscript. Y.L., Y.G., J.C., M.L., X.W., Q.N, J.Z. and W.X. performed sample collection and cell experiments. All authors reviewed and approved the manuscript.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Lei, Y. *et al.* GLCCI1 rs37973: a potential genetic predictor of therapeutic response to inhaled corticosteroids in Chinese chronic obstructive pulmonary disease patients. *Sci. Rep.* 7, 42552; doi: 10.1038/srep42552 (2017).

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017